{"id":"concurrent-chemotherapy-with-docetaxel","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Neutropenia"},{"rate":"20-40%","effect":"Anemia"},{"rate":"10-30%","effect":"Thrombocytopenia"},{"rate":"20-40%","effect":"Fatigue"},{"rate":"10-30%","effect":"Nausea"},{"rate":"10-30%","effect":"Vomiting"},{"rate":"10-30%","effect":"Diarrhea"},{"rate":"10-30%","effect":"Constipation"},{"rate":"5-20%","effect":"Mucositis"},{"rate":"5-20%","effect":"Neuropathy"}]},"_chembl":{"chemblId":"CHEMBL92","moleculeType":"Small molecule","molecularWeight":"807.89"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Docetaxel binds to tubulin and prevents the formation of microtubules, which are essential for cell division. This leads to cell cycle arrest and apoptosis in rapidly dividing cancer cells. The exact mechanism of action is not fully understood, but it is thought to involve the inhibition of microtubule dynamics and the induction of apoptosis.","oneSentence":"Docetaxel works by inhibiting microtubule dynamics, thereby inducing apoptosis in cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:07:24.199Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Breast cancer"},{"name":"Prostate cancer"},{"name":"Ovarian cancer"}]},"trialDetails":[{"nctId":"NCT07496190","phase":"PHASE2","title":"Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-03-01","conditions":"Nasopharyngeal Cancinoma (NPC)","enrollment":59},{"nctId":"NCT07322263","phase":"PHASE2","title":"Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC","status":"NOT_YET_RECRUITING","sponsor":"Michael A. O'Donnell","startDate":"2026-04-01","conditions":"Bladder Cancer, Non-Muscle Invasive Bladder Cancer (NMIBC), Urothelial Carcinoma","enrollment":174},{"nctId":"NCT01810913","phase":"PHASE2, PHASE3","title":"Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-03-22","conditions":"Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7","enrollment":613},{"nctId":"NCT01928589","phase":"NA","title":"Partial Irradiation and Sequential vs. Concurrent Chemo Early Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Richard Zellars","startDate":"2014-01-16","conditions":"Breast Cancer, Adenocarcinoma of the Breast","enrollment":81},{"nctId":"NCT06078709","phase":"PHASE2","title":"Preoperative Hypofractionated Radiotherapy With FOLFOX for Esophageal or Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2023-11-20","conditions":"Clinical Stage I Esophageal Adenocarcinoma AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage II Esophageal Adenocarcinoma AJCC v8","enrollment":99},{"nctId":"NCT07410234","phase":"PHASE2","title":"Phase II Exploratory Study of Toripalimab Combined With SBRT in HER2-Negative Breast Cancer Patients With Insensitivity to Neoadjuvant Chemotherapy","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-02-21","conditions":"Breast Cancer","enrollment":110},{"nctId":"NCT06592599","phase":"PHASE2","title":"Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)","status":"RECRUITING","sponsor":"Stanford University","startDate":"2024-09-03","conditions":"Nasopharyngeal Carcinoma","enrollment":24},{"nctId":"NCT07392320","phase":"PHASE2","title":"A Phase II Trial Comparing Immunotherapy Versus Capecitabine Maintenance After Chemo-chemoradiotherapy for High-risk Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-02-04","conditions":"Nasopharangeal Cancer","enrollment":142},{"nctId":"NCT07214987","phase":"PHASE2","title":"PDT For Induction Therapy For Head And Neck Cancer","status":"NOT_YET_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2026-03-09","conditions":"Squamous Cell Carcinoma, Head and Neck Cancer Squamous Cell Carcinoma, Head and Neck Cancer","enrollment":26},{"nctId":"NCT07371897","phase":"PHASE3","title":"Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-06-30","conditions":"Head and Neck Squamous Cell Carcinoma HNSCC","enrollment":154},{"nctId":"NCT03801876","phase":"PHASE3","title":"Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2019-06-26","conditions":"Clinical Stage I Esophageal Adenocarcinoma AJCC v8, Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8","enrollment":300},{"nctId":"NCT04028167","phase":"PHASE2","title":"Induction FLOT With CROSS CRT for Esophageal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2020-04-08","conditions":"Adenocarcinoma Esophagus, Adenocarcinoma of the Gastroesophageal Junction","enrollment":40},{"nctId":"NCT07317778","phase":"PHASE2","title":"Chemotherapy With or Without Adebrelimab and T-DXh as Neoadjuvant Therapy for HR+/HER2 Low Early Stage Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-02-15","conditions":"Breast Cancer Early Stage Breast Cancer (Stage 1-3), HR Positive/HER2 Low Breast Cancer","enrollment":249},{"nctId":"NCT05494190","phase":"NA","title":"The Management of Metastatic Neck Nodes in N2/3 Hypopharyngeal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Eye & ENT Hospital of Fudan University","startDate":"2022-11-01","conditions":"Hypopharyngeal Carcinoma","enrollment":111},{"nctId":"NCT05142189","phase":"PHASE1","title":"Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2022-06-17","conditions":"Non-Small Cell Lung Cancer","enrollment":280},{"nctId":"NCT04329065","phase":"PHASE2","title":"Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer","status":"RECRUITING","sponsor":"University of Washington","startDate":"2022-04-20","conditions":"Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8","enrollment":25},{"nctId":"NCT04615013","phase":"PHASE1","title":"NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-11-23","conditions":"Cervical Esophagus Adenocarcinoma, Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8","enrollment":24},{"nctId":"NCT04722523","phase":"PHASE1","title":"A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-01-20","conditions":"Head and Neck Cancer, Head Cancer, Head Cancer Neck","enrollment":40},{"nctId":"NCT06531434","phase":"PHASE1, PHASE2","title":"Establishing Best Treatment Strategy for T4 Esophageal Cancer","status":"RECRUITING","sponsor":"National Cheng-Kung University Hospital","startDate":"2024-08-01","conditions":"Esophageal Cancer TNM Staging Primary Tumor (T) T4","enrollment":22},{"nctId":"NCT06207981","phase":"PHASE3","title":"Phase III Study Evaluating Induction Chemotherapy Followed by Chemoradiotherapy Compared to Standard Chemoradiotherapy for Locally Advanced SCCA","status":"RECRUITING","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2024-02-26","conditions":"Anal Cancer","enrollment":310},{"nctId":"NCT00334815","phase":"PHASE2","title":"Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2006-06-15","conditions":"Lung Adenocarcinoma, Lung Adenosquamous Carcinoma, Lung Large Cell Carcinoma","enrollment":29},{"nctId":"NCT06520345","phase":"PHASE3","title":"The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)","status":"RECRUITING","sponsor":"Telix Pharmaceuticals (Innovations) Pty Limited","startDate":"2024-07-26","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":430},{"nctId":"NCT07041788","phase":"PHASE2","title":"Iparomlimab and Tuvonralimab Combined With SFRT and Definitive Chemoradiotherapy in Locoregionally Advanced Bulky HNSCC","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital of Nanchang University","startDate":"2025-07-10","conditions":"Cancer","enrollment":25},{"nctId":"NCT04634877","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-01-10","conditions":"Endometrial Neoplasms","enrollment":990},{"nctId":"NCT00405405","phase":"PHASE1","title":"Phase I of Biologics and Chemoradiation Therapy for Advanced Head and Neck Cancer","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2006-12","conditions":"Head and Neck Cancer, Parotid Gland Cancer, Thyroid Gland Cancer","enrollment":13},{"nctId":"NCT06003075","phase":"PHASE2","title":"Induction Chemo-Nivo in Unresectable Stage III NSCLC","status":"TERMINATED","sponsor":"Ralph G Zinner","startDate":"2023-12-13","conditions":"Lung Cancer, Nonsmall Cell, Lung Cancer Stage III","enrollment":1},{"nctId":"NCT05527782","phase":"PHASE2","title":"Induction Modified TPF Followed by Concurrent Chemoradiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hospital Universitario Doctor Peset","startDate":"2019-05-01","conditions":"Locally Advanced Head and Neck Squamous Cell Carcinoma","enrollment":40},{"nctId":"NCT05508347","phase":"PHASE2","title":"Nituzumab (Taixinsheng ®） A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Study on the Efficacy and Safety of Combined Induction Chemotherapy for Locally Advanced Nasopharyngeal Carcinomatreatment of Locally Advanced Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Sichuan Cancer Hospital and Research Institute","startDate":"2022-04-20","conditions":"Nasopharyngeal Carcinoma","enrollment":170},{"nctId":"NCT00490139","phase":"PHASE3","title":"ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-05-16","conditions":"Neoplasms, Breast","enrollment":8381},{"nctId":"NCT00544414","phase":"PHASE2","title":"Chemotherapy Followed by Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Head And Neck Cancer","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2000-06-07","conditions":"Head and Neck Cancer","enrollment":31},{"nctId":"NCT04375605","phase":"PHASE3","title":"Neoadjuvant RCT Versus CT for Patients With Locally Advanced, Potentially Resectable Adenocarcinoma of the GEJ","status":"ACTIVE_NOT_RECRUITING","sponsor":"Universitätsmedizin Mannheim","startDate":"2020-06-03","conditions":"Gastroesophageal Junction Adenocarcinoma","enrollment":342},{"nctId":"NCT05060471","phase":"PHASE2","title":"PD-1 Blockade Combined with Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced SCCA Patients","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2021-10-27","conditions":"Anal Canal Cancer, Anal Squamous Cell Carcinoma, Anal Cancer","enrollment":25},{"nctId":"NCT02229084","phase":"PHASE1, PHASE2","title":"Vaccination of High Risk Breast Cancer Patients","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2015-01-14","conditions":"Breast Cancer, Breast Neoplasms","enrollment":58},{"nctId":"NCT05517135","phase":"","title":"tReatment Individualisation By EBV stratificatiON in Nasopharyngeal Carcinoma: an Umbrella Platform Study (RIBBON-Umbrella)","status":"RECRUITING","sponsor":"National Cancer Centre, Singapore","startDate":"2022-11-17","conditions":"Nasopharyngeal Carcinoma","enrollment":1000},{"nctId":"NCT01404156","phase":"PHASE2, PHASE3","title":"Preoperative Chemotherapy vs. Chemoradiation in Esophageal / GEJ Adenocarcinoma","status":"COMPLETED","sponsor":"Dr. Gordon Buduhan","startDate":"2015-09","conditions":"Esophageal Cancer, Adenocarcinoma, Esophageal, Adenocarcinoma, Gastroesophageal Junction","enrollment":29},{"nctId":"NCT06554028","phase":"PHASE2","title":"Tislelizumab and Induction Chemotherapy for Larynx Preservation in Resectable Advanced Laryngeal/Hypopharyngeal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2024-08","conditions":"Laryngeal Cancer, Hypopharynx Cancer, Laryngeal Neoplasms","enrollment":46},{"nctId":"NCT02776163","phase":"PHASE2","title":"Postoperative Concurrent Chemoradiotherapy in Treating Patients With High-Risk Salivary Gland Carcinomas","status":"COMPLETED","sponsor":"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","startDate":"2016-06-01","conditions":"Salivary Gland Tumors, Head and Neck Cancer","enrollment":107},{"nctId":"NCT02923258","phase":"PHASE2, PHASE3","title":"Postoperative CCRT With Docetaxel vs Cisplatin in High Risk Oral Cavity Cancer","status":"COMPLETED","sponsor":"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","startDate":"2018-04-21","conditions":"Oral Cavity Squamous Cell Carcinoma","enrollment":224},{"nctId":"NCT06424899","phase":"PHASE2","title":"A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC","status":"RECRUITING","sponsor":"Zeng Jian","startDate":"2024-05-19","conditions":"Non Small Cell Lung Cancer","enrollment":92},{"nctId":"NCT02509286","phase":"PHASE3","title":"Perioperative Chemotherapy Compared To Neoadjuvant Chemoradiation in Patients With Adenocarcinoma of the Esophagus","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital Schleswig-Holstein","startDate":"2016-01","conditions":"Esophageal Adenocarcinoma (UICC TNM7), Adenocarcinoma of the Esophagogastric Junction","enrollment":438},{"nctId":"NCT04085250","phase":"PHASE2","title":"Study of Nivolumab for Non-Small Cell Lung Cancer (Stage III) Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent Chemoradiation Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2019-11-28","conditions":"Stage III Non-small-cell Lung Cancer","enrollment":264},{"nctId":"NCT04212052","phase":"PHASE2","title":"Split-course Hypofractionated Radiotherapy With Concurrent Chemotherapy in Locally Advanced Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2020-07-01","conditions":"Non-small Cell Lung Cancer","enrollment":104},{"nctId":"NCT03326947","phase":"PHASE2","title":"Phage II Trial of Stathmin as Predictive Biomarker for TPF Induction Chemotherapy in OSCC","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2018-01-01","conditions":"Neoplasm Neck","enrollment":60},{"nctId":"NCT02465736","phase":"PHASE3","title":"Study of Docetaxel or Vinorelbine Plus Cisplatin in Neoadjuvant Chemoradiotherapy for Esophageal Cancer (NEOCRTEC308)","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2015-07","conditions":"Esophageal Squamous Cell Carcinoma, Esophageal Cancer, Oesophageal Cancer","enrollment":610},{"nctId":"NCT03600831","phase":"PHASE2, PHASE3","title":"Postoperative Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Patients With Locoregionally Advanced Esophageal Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"Huai'an First People's Hospital","startDate":"2018-08-20","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":434},{"nctId":"NCT04951063","phase":"PHASE1","title":"Fraction Dose Escalation of Hypo-fractionated Radiotherapy in LANSCLC","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2021-06-01","conditions":"Locally Advanced Lung Carcinoma","enrollment":18},{"nctId":"NCT03673657","phase":"PHASE2","title":"Study of Early Nutritional Intervention During Concurrent Chemoradiotherapy for Local Advanced Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2018-08-10","conditions":"Local Advanced Non-small Cell Lung Cancer","enrollment":67},{"nctId":"NCT06156891","phase":"PHASE2","title":"PD-1 Inhibitor Based Induction Chemotherapy Followed by De-escalation Protocols in OPSCC","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2022-06-29","conditions":"Oropharyngeal Cancer","enrollment":60},{"nctId":"NCT06136988","phase":"PHASE1, PHASE2","title":"A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma.","status":"NOT_YET_RECRUITING","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2023-12","conditions":"Locally Advanced Unresectable Esophageal Squamous Carcinoma","enrollment":129},{"nctId":"NCT04165993","phase":"PHASE2","title":"Study of KN026 Monotherapy or Combination Therapy in Patients With Metastatic Breast Cancer","status":"UNKNOWN","sponsor":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","startDate":"2019-12-31","conditions":"Metastatic Breast Cancer","enrollment":68},{"nctId":"NCT03737123","phase":"PHASE2","title":"Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma","status":"TERMINATED","sponsor":"Nabil Adra","startDate":"2018-12-19","conditions":"Urothelial Carcinoma","enrollment":6},{"nctId":"NCT04156698","phase":"PHASE2","title":"Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Eye & ENT Hospital of Fudan University","startDate":"2020-05-21","conditions":"Hypopharyngeal Carcinoma, Immunotherapy, Chemotherapy","enrollment":51},{"nctId":"NCT03919552","phase":"PHASE3","title":"Cisplatin-based and Carboplatin-based Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2018-01-31","conditions":"Cisplatin, Carboplatin, NPC","enrollment":482},{"nctId":"NCT00318903","phase":"PHASE2","title":"Irinotecan and Taxotere With Radiotherapy as Preoperative Treatment in Resectable Esophageal Cancer","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2002-01","conditions":"Esophageal Cancer, Cancer of the Esophagus, Esophagus Cancer","enrollment":25},{"nctId":"NCT05860868","phase":"PHASE3","title":"Two Cycles VS Three Cycles Induction Chemotherapy in T1-4N2-3 Locally Advanced Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"First Affiliated Hospital, Sun Yat-Sen University","startDate":"2023-05","conditions":"Locally Advanced Nasopharyngeal Carcinoma","enrollment":474},{"nctId":"NCT00301808","phase":"PHASE2","title":"Cisplatin, Pemetrexed Disodium, and Radiation Therapy Followed by Docetaxel in Treating Patients With Stage III Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Barbara Ann Karmanos Cancer Institute","startDate":"2005-11","conditions":"Lung Cancer","enrollment":29},{"nctId":"NCT05800054","phase":"NA","title":"Effect of NST Whole-course Nutritional Management on Nutritional Status and Adverse Reactions in Esophageal Cancer","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2021-01-01","conditions":"Esophageal Neoplasms, Adverse Drug Event","enrollment":210},{"nctId":"NCT03904563","phase":"PHASE2","title":"Bevacizumab After Chemoradiotherapy For Locally Advanced Lung Adenocarcinoma","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2019-01-01","conditions":"Lung Adenocarcinoma","enrollment":27},{"nctId":"NCT00773695","phase":"PHASE2","title":"A Study of Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-11-07","conditions":"Breast Cancer","enrollment":150},{"nctId":"NCT03661567","phase":"PHASE2","title":"Methylprednisolone After Split-course Chemoradiotherapy For Bulky Local Advanced None-small Cell Lung Cancer","status":"TERMINATED","sponsor":"Sun Yat-sen University","startDate":"2018-08-09","conditions":"Non-small Cell Lung Cancer","enrollment":52},{"nctId":"NCT05481775","phase":"PHASE2","title":"Evaluating Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy for Locally Advanced Non-small Cell Lung Cancer","status":"WITHDRAWN","sponsor":"Sun Yat-sen University","startDate":"2022-04-01","conditions":"Locally Advanced Non-small Cell Lung Cancer, Efficacy and Safety","enrollment":""},{"nctId":"NCT05622474","phase":"NA","title":"A Multicenter Randomized Controlled Clinical Study on the Treatment of T3N1M0 High Risk Nasopharyngeal Carcinoma With or Without Induction Chemotherapy Before Concurrent Radiotherapy and Chemotherapy","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2022-11-30","conditions":"Nasopharyngeal Carcinoma","enrollment":236},{"nctId":"NCT03900117","phase":"PHASE2","title":"Hypofractionated Radiotherapy Followed by Hypo-boost for Local Advanced NSCLC","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2019-03-01","conditions":"Non-small Cell Lung Cancer","enrollment":77},{"nctId":"NCT05472467","phase":"PHASE2","title":"Camrelizumab Combination With SBRT and Concurrent Chemotherapy Treated Stage IV Oligometastatic Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Sichuan Cancer Hospital and Research Institute","startDate":"2021-12-21","conditions":"Non-small Cell Lung Cancer Metastatic","enrollment":35},{"nctId":"NCT00288080","phase":"PHASE3","title":"Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2005-12","conditions":"Prostate Cancer","enrollment":612},{"nctId":"NCT04437329","phase":"PHASE3","title":"Nedaplatin Versus Cisplatin in Treatment for Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Affiliated Cancer Hospital & Institute of Guangzhou Medical University","startDate":"2020-08-01","conditions":"Nasopharyngeal Carcinoma","enrollment":352},{"nctId":"NCT04834206","phase":"PHASE2","title":"Nedaplatin in Treatment for Nasopharyngeal Carcinoma","status":"COMPLETED","sponsor":"Affiliated Cancer Hospital & Institute of Guangzhou Medical University","startDate":"2021-05-01","conditions":"Nasopharyngeal Carcinoma","enrollment":32},{"nctId":"NCT04508816","phase":"PHASE2","title":"Anti-EGFR Therapy Plus IMRT Concurrent Chemoradiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy","status":"COMPLETED","sponsor":"Fudan University","startDate":"2016-01-01","conditions":"Nasopharyngeal Carcinoma","enrollment":45},{"nctId":"NCT04508829","phase":"PHASE2","title":"Anti-EGFR Therapy With IMRT Concurrent Chemoradiotherapy in Locally Advanced OPC Resistant to Induction Chemotherapy","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2016-01-01","conditions":"Oropharyngeal Carcinoma","enrollment":52},{"nctId":"NCT04958993","phase":"PHASE1, PHASE2","title":"A Trial of Anlotinib Combined With Concurrent Chemoradiotherapy in Patients With Unresectable Stage III Non-small Cell Lung Cancer","status":"TERMINATED","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2020-11-12","conditions":"Non-small Cell Lung Cancer","enrollment":7},{"nctId":"NCT01889303","phase":"PHASE2","title":"Phase II Study of DC Versus 5-FU/CF as Chemotherapy and Concurrent Chemoradiotherapy for Locally Advanced Gastric Cancer","status":"UNKNOWN","sponsor":"Wuhan University","startDate":"2013-05","conditions":"Gastric Cancer","enrollment":100},{"nctId":"NCT05232552","phase":"PHASE2","title":"Study of Anlotinib With Chemoradiation for Patients With Locally Advanced Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2021-01-01","conditions":"Nasopharyngeal Carcinoma","enrollment":37},{"nctId":"NCT03659578","phase":"PHASE2","title":"Study of Thymosin α1 to Reduce Acute Pneumonia For Bulky None-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2018-08-09","conditions":"Non-small Cell Lung Cancer","enrollment":69},{"nctId":"NCT03663764","phase":"PHASE2","title":"Hypofractionated Chemoradiotherapy and Thymosin α1 in Unresectable or Recurrent Thymic Epithelial Tumor","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2018-08-13","conditions":"Thymoma and Thymic Carcinoma","enrollment":57},{"nctId":"NCT00193128","phase":"PHASE1, PHASE2","title":"Preoperative Therapy With Oxaliplatin/Docetaxel/Capecitabine and Radiation in Resectable Esophagus Cancer","status":"COMPLETED","sponsor":"SCRI Development Innovations, LLC","startDate":"2004-04","conditions":"Esophagus Cancer","enrollment":59},{"nctId":"NCT02512315","phase":"PHASE3","title":"A Trial On 4 Cycles Of Neoadjuvant Chemotherapy Plus Concurrent Chemoradiation In N2-3 Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2015-08","conditions":"Nasopharyngeal Carcinoma","enrollment":192},{"nctId":"NCT04867330","phase":"NA","title":"Toripalimab Based Induction Chemotherapy Followed by De-escalation Protocols in HPV-related OPSCC","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2021-02-01","conditions":"Oropharyngeal Carcinoma, Immune Checkpoint Inhibitor, De-escalation","enrollment":46},{"nctId":"NCT00896181","phase":"PHASE2","title":"Phase 2 Sequential and Concurrent Chemoradiation for Advanced Nasopharyngeal Carcinoma (NPC)","status":"COMPLETED","sponsor":"Stanford University","startDate":"2008-12-10","conditions":"Stage II Lymphoepithelioma of the Nasopharynx, Stage II Squamous Cell Carcinoma of the Nasopharynx, Stage III Lymphoepithelioma of the Nasopharynx","enrollment":26},{"nctId":"NCT01126008","phase":"PHASE2","title":"Concomitant Chemoradiotherapy (CCRT) With Weekly Docetaxel and Cisplatin for Locally Advanced Head and Neck Cancer","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2009-11-16","conditions":"Head and Neck Cancer","enrollment":44},{"nctId":"NCT04782765","phase":"PHASE2","title":"Phase Ⅱ Trial of Camrelizumab in Patients Without Distant Metastasis Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2021-03-20","conditions":"Disease-free Survival Rate","enrollment":59},{"nctId":"NCT03986463","phase":"","title":"CIrculating Tumour DNA in Lung Cancer (CITaDeL): Optimizing Sensitivity and Clinical Utility","status":"COMPLETED","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2019-05-01","conditions":"Lung Neoplasms, Lung Cancer, Neoplasm of Lung","enrollment":40},{"nctId":"NCT02577341","phase":"PHASE2","title":"Nimotuzumab Combined With Chemoradiotherapy for Unresectable Locally Advanced Squamous Cell Lung Cancer","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2015-08","conditions":"Non-small-cell Lung Cancer","enrollment":122},{"nctId":"NCT03908372","phase":"PHASE2, PHASE3","title":"Optimized Treatment Strategies for Early and Medium Stage Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2019-06-15","conditions":"Stage II, III, Nasopharyngeal Squamous Cell Carcinoma, Induction Chemotheray","enrollment":120},{"nctId":"NCT03006575","phase":"PHASE2","title":"Study of Split-course Chemoradiotherapy For Postoperative Locoregional Recurrence Of Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2015-08","conditions":"Non-small Cell Lung Cancer","enrollment":57},{"nctId":"NCT02640898","phase":"NA","title":"Docetaxel-based Chemoradiotherapy Plus Periradiation Chemotherapy Compared With INT 0116 Adjuvant Arm in Gastric Cancer","status":"UNKNOWN","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2015-12","conditions":"Gastric Cancer","enrollment":500},{"nctId":"NCT04502641","phase":"PHASE3","title":"Induction Chemotherapy in Locally Advanced Hypopharyngeal Carcinoma: a Randomised Phase 3 Trial","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2020-08-01","conditions":"Hypopharyngeal Cancer","enrollment":160},{"nctId":"NCT02575547","phase":"","title":"Effect of Chemoradiotherapy on Nutritional Status in Advanced NPC Patients","status":"COMPLETED","sponsor":"Zhao Chong","startDate":"2015-06","conditions":"Nasopharyngeal Carcinoma, Malnutrition","enrollment":186},{"nctId":"NCT04138992","phase":"PHASE2, PHASE3","title":"A Study on the Efficacy and Safety of Bevacizumab in Untreated Patients With Locally Advanced Cervical Cancer","status":"UNKNOWN","sponsor":"Air Force Military Medical University, China","startDate":"2020-08-01","conditions":"Disease Free Survival","enrollment":150},{"nctId":"NCT02627807","phase":"NA","title":"Clinical Target Volume Based on Disease Extension Risk Atlas and Computer-aided Delineation in Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2015-12","conditions":"Nasopharyngeal Neoplasms","enrollment":386},{"nctId":"NCT04414566","phase":"PHASE3","title":"Induction Chemotherapy Plus Radiotherapy Alone in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"West China Hospital","startDate":"2020-06-01","conditions":"Nasopharyngeal Carcinoma","enrollment":562},{"nctId":"NCT02403531","phase":"PHASE2","title":"Induction Chemotherapy Followed by Chemoradiotherapy in Esophageal Cancer","status":"COMPLETED","sponsor":"Mian XI","startDate":"2015-05-01","conditions":"Neoplasms","enrollment":110},{"nctId":"NCT01102088","phase":"PHASE1","title":"Simultaneous Integrated Boost (SIB) in Esophageal Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2010-04","conditions":"Esophageal Cancer","enrollment":61},{"nctId":"NCT02573506","phase":"PHASE2","title":"Study of Split-course Chemoradiotherapy For Locally Advanced None-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2015-08","conditions":"Non-small Cell Lung Cancer","enrollment":99},{"nctId":"NCT03177174","phase":"NA","title":"Different Chemotherapy Protocols Combined With Intensity Modulated Radiation Therapy in Patients With Locally Advanced Nasopharyngeal Carcinoma","status":"COMPLETED","sponsor":"Luo yanrong","startDate":"2017-06-12","conditions":"Drug-Related Side Effects and Adverse Reactions","enrollment":150},{"nctId":"NCT01312350","phase":"PHASE2","title":"Neoadjuvant Chemotherapy for Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN)","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2010-11","conditions":"Hypopharyngeal Cancer","enrollment":40},{"nctId":"NCT04158518","phase":"NA","title":"De-escalation Protocols in Locoregionally Advanced Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Chaosu Hu","startDate":"2019-11-01","conditions":"Nasopharyngeal Carcinoma","enrollment":118},{"nctId":"NCT04137679","phase":"PHASE2","title":"Efficacy and Safety of Neo-CRT Followed Surgery Compared With Definitive CRT in Patients With Initial Unresectable ESO","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2019-11-01","conditions":"Unresectable Esophageal Cancer","enrollment":60},{"nctId":"NCT02721576","phase":"PHASE4","title":"A Trial of CMNa Combined With Concurrent Chemoradiotherapy for Locally Recurrent ESCC","status":"TERMINATED","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2016-07-05","conditions":"Esophageal Neoplasms","enrollment":8},{"nctId":"NCT02721563","phase":"PHASE4","title":"A Trial of CMNa Combined With Definitive Concurrent Chemoradiotherapy for Locally Advanced ESCC","status":"COMPLETED","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2016-02-25","conditions":"Esophageal Neoplasms","enrollment":77},{"nctId":"NCT02721550","phase":"PHASE4","title":"A Trial of CMNa Combined With Preoperatie Concurrent Chemoradiotherapy for Locally Advanced ESCC","status":"TERMINATED","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2016-08-01","conditions":"Esophageal Neoplasms","enrollment":2}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["docetaxel"],"phase":"phase_3","status":"active","brandName":"concurrent chemotherapy with docetaxel","genericName":"concurrent chemotherapy with docetaxel","companyName":"Air Force Military Medical University, China","companyId":"air-force-military-medical-university-china","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Docetaxel works by inhibiting microtubule dynamics, thereby inducing apoptosis in cancer cells. Used for Non-small cell lung cancer, Breast cancer, Prostate cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}